Abstract
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
Highlights
Chemotherapy consisted of CDDP 120 mg m-2 as a 30 min infusion in 3% hypertonic saline with hydration and mannitol diuresis on day 1, VDS 3 mg m2 on day 2 as an i.v. bolus and DTIC 250 mg m2 on days 2-6 as an i.v. infusion over 30 min
The response to therapy was as follows: complete response (CR) five (19%) patients, partial response (PR) seven (26%), stable (SD) or progressive disease (PD) 15 (55%)
Metastases in the lungs, lymph nodes, subcutaneous tissues and skin were more responsive to chemotherapy
Summary
Entry criteria included histologically documented melanoma, age < 75 years, ECOG performance status of 0-2, predicted survival > 2 months, no prior chemotherapy and creatinine clearance > 60 ml min-'. Chemotherapy consisted of CDDP 120 mg m-2 as a 30 min infusion in 3% hypertonic saline with hydration and mannitol diuresis on day 1, VDS 3 mg m2 (no more than 5 mg) on day 2 as an i.v. bolus and DTIC 250 mg m2 on days 2-6 as an i.v. infusion over 30 min. Antiemetic treatment with metoclopramide 2 mg kg-' 0.5 h before and 1.5, 3.5, 5.5 and 8 h after CDDP administration plus dexamethasone 8 mg 3 h before and 3, 6 and 9 h after CDDP administration was given. On days 2-6 metoclopramide 2 mg kg-' plus dexamethasone 8 mg 0.5 h before and 3 h after DTIC administration were given
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
